USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
IMMUNOTOPE, INC.
Address:
THE PENNSYLVANIA BIOTECHNOLOGY CENTER
3805 OLD EASTON ROAD
DOYLESTOWN, PA
Phone:
(215) 357-1814
URL:
N/A
EIN:
175309184
DUNS:
131080983
Number of Employees:
9
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,468,000.00 4
SBIR Phase II $3,704,009.00 2
STTR Phase I $704,653.00 3
STTR Phase II $1,082,150.00 1

Award List:

Autoantibodies as serum biomarkers for prostate cancer diagnosis and prognosis

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Ramila Philip, Chief Scientific Officer
Abstract:
Prostate cancer is the most commonly diagnosed form of cancer and the second leading cause of cancer-related death in males. A highly sensitive, selective, noninvasive screening assay is needed to diagnose prostate cancer and to monitor effectiveness of treatment or recurrence. We propose to… More

Identification of auto antigens in ovarian cancer

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Early diagnosis and immunotherapeutic stimulation of a patient's own immune system to detect and destroy tumors is the best hope for the treatment, prevention and eventual cure for ovarian cancer. The overall goal of this proposal is to conduct… More

Autoantibodies as serum biomarkers for prostate cancer diagnosis and prognosis

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$730,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Ramila Philip, Chief Scientific Officer
Abstract:
Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer-related death in males. A highly sensitive, selective, noninvasive screening assay is needed to diagnose prostate cancer and to monitor effectiveness of treatment or recurrence. We are developing a diagnostic… More

HCC diagnostics defined by fucosylated serum biomarkers

Award Year / Program / Phase:
2006 / STTR / Phase I
Award Amount:
$216,299.00
Agency:
HHS
Principal Investigator:
Research Institution:
DREXEL UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop a novel early detection diagnostic for hepatocellular carcinoma based on the detection of glycoproteins that have increased levels of fucosylation in the sera of patients. With our colleagues at Drexel University,… More

Defining T cell epitopes in Dengue virus infection

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$599,995.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live… More

HCC diagnostics defined by fucosylated serum biomarkers

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$1,082,150.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Our over-all goal has been to develop a diagnostic test for the early detection of liver cancer (hepatocellular carcinoma (HCC)) that is more specific and sensitive than existing, approved diagnostic tests and procedure s. Using glycoproteomic discovery methods,… More

Novel Biomarkers Assessment in the Progression from Androgen Dependent Prostate Cancer to Androgen Independent Prostate Cancer

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Anand Mehta, Associate Professor
Research Institution:
DREXEL UNIV.
RI Contact:
Margaret Vigiolto
Abstract:
Prostate cancer is the most commonly diagnosed form of cancer and the second leading cause of cancer-related death in males. Treatment with androgen ablation therapy after radical prostatectomy (RP) eventually leads to relapse and development of androgen-independent disease. Patients with androgen… More

Synthetic Nanoparticle based Universal Influenza Vaccine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$598,005.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Influenza viruses are highly infectious RNA viruses that cause epidemic respiratory disease in the human population. There is an urgent unmet need for an influenza vaccine with greater potency, durability of antibody re sponse, and strain-cross reactivity that… More

Defining T cell epitopes in Dengue virus infection

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$2,974,009.00
Agency:
HHS
Principal Investigator:
Ramila Philip – 215-489-4955
Abstract:
DESCRIPTION (provided by applicant): There is a well-recognized need to develop vaccines that stimulates humoral immunity as well as a potent T cell immunity in order to achieve protection from infection with pathogens. Although numerous investigations arefocused on developing vaccines that induce… More

Novel liver fibrosis test for early detection and classification

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$388,354.00
Agency:
HHS
Principal Investigator:
Anand S. Mehta – 215-489-4905
Research Institution:
DREXEL UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients.… More